Home
    • Plans Blog Contact
    Relmada Therapeutics Inc logo

    Relmada Therapeutics Inc

    RLMD
    Last price US$4.80
    Market cap US$415.7m
    12M price change N/A
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Halozyme Therapeutics IncHALO Industry peer Corcept Therapeutics IncorporatedCORT Industry peer Exelixis IncEXEL Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Relmada Therapeutics Inc Overview

    Industry: Biotechnology

    Sector: Healthcare

    Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida. Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Relmada Therapeutics Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Aug 06, 2026

    Quarterly result summary

    Net loss was -$12.9M. Cash was $217.7M.

    Net loss -$12.9M reported
    Cash $217.7M reported

    What changed

    • Review the SEC source filing for the full reported results and management commentary.

    Guidance / outlook

    The Company expects to submit the NDV-01 IND by year-end 2026 and initiate the Phase 3 RESCUE registrational program upon IND clearance.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing CURRENT REPORT Aug 06, 2026 SEC filing QUARTERLY REPORT Aug 06, 2026 Earnings material CORPORATE PRESENTATION DATED AUGUST 6, 2026 Aug 06, 2026 Earnings release PRESS RELEASE DATED MAY 12, 2026, REGARDING CORPORATE UPDATE AND FULL YEAR 2025 FINANCIAL RESULTS May 12, 2026 Earnings material CORPORATE PRESENTATION DATED MAY 12, 2026 May 12, 2026 SEC filing CURRENT REPORT May 12, 2026 SEC filing QUARTERLY REPORT May 12, 2026 SEC filing CURRENT REPORT Mar 20, 2026 Earnings release PRESS RELEASE DATED MARCH 19, 2026, REGARDING CORPORATE UPDATE AND FULL YEAR 2025 FINANCIAL RESULTS Mar 20, 2026 Earnings material CORPORATE PRESENTATION DATED MARCH 19, 2026 Mar 20, 2026 SEC filing ANNUAL REPORT Mar 19, 2026

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 3.00/5
    Relmada Therapeutics Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score 0.00/5
    Relmada Therapeutics Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Relmada Ther... RLMD US$415.7m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.21/5
    Relmada Therapeutics Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Relmada Ther... RLMD US$415.7m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 2.99/5
    Relmada Therapeutics Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Relmada Ther... RLMD US$415.7m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Reported currency
    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Relmada Therapeutics Inc logo

    Relmada Therapeutics Inc

    US$4.80

    US$415.7m

    -2.83%

    N/A